Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9BWT1
UPID:
CDCA7_HUMAN
Alternative names:
Protein JPO1
Alternative UPACC:
Q9BWT1; B4DLP8; B4DV66; Q53EW5; Q580W9; Q658K4; Q658N4; Q8NBY9; Q96BV8; Q96SP5
Background:
Cell division cycle-associated protein 7, also known as Protein JPO1, plays a pivotal role in MYC-mediated cell transformation and apoptosis. It promotes anchorage-independent growth and enhances clonogenicity in lymphoblastoid cells. While not directly tumorigenic when overexpressed, it significantly contributes to MYC-mediated tumorigenesis and may act as a transcriptional regulator.
Therapeutic significance:
The protein is linked to Immunodeficiency-centromeric instability-facial anomalies syndrome 3, a rare disorder with symptoms including recurrent infections and growth retardation. Understanding the role of Cell division cycle-associated protein 7 could open doors to potential therapeutic strategies for this syndrome.